Preparation of Sorafenib Self-Microemulsifying Drug Delivery System and Its Relative Bioavailability in Rats

Ya-Ou Liu,Jie-Ming Fan,Xue-Qing Wang,Qiang Zhang
DOI: https://doi.org/10.5246/jcps.2011.02.021
2011-01-01
Abstract:Sorafenib is a novel antittmror drug, which is poorly absorbed in the gastrointestinal tract due to its low solubility in water. To improve the bioavailability of sorafenib, a self-microemulsifying drug delivery system(SMEDDS)formulation of sorafenib was prepared and its relative bioavailability in rats was evaluated. The blank SMEDDS was prepared from a mixture of ethyl oleate(oil phase, 20%, w/w), Cremophol EL(surfactant, 48%, w/w), PEG-400(co-surfactant, 16%, w/w)and ethanol (co-surfactant, 16%, w/w). Sorafenib was subsequently dissolved in the blank SMEDDS to obtain a sorafenib SMEDDS formulation with a final sorafenib concentration at 20 mg/mL. The particle size of the emulsified sorafenib SMEDDS was about 20-25 nm.Compared with sorafenib suspension, the prepared SMEDDS formulation exhibited no effect on the Tmax, but significantly increased the AUC, C. and MRT and decreased the drug clearance. Most importantly, the oral bioavailability based on AUC0-72h increased about 25 times after formulating sorafenib in SMEDDS. We concluded that SMEDDS could be a promising vesicle for the oral delivery of the poorly soluble antitumor drug sorafenib.
What problem does this paper attempt to address?